Home084990 • KOSDAQ
Helixmith Co Ltd
â‚©2,815.00
Jan 14, 6:36:44 PM GMT+9 · KRW · KOSDAQ · Disclaimer
StockKR listed security
Previous close
â‚©2,845.00
Day range
â‚©2,795.00 - â‚©2,870.00
Year range
â‚©2,500.00 - â‚©7,440.00
Market cap
129.75B KRW
Avg Volume
73.24K
P/E ratio
-
Dividend yield
-
Primary exchange
KOSDAQ
Market news
Financials
Income Statement
Revenue
Net income
(KRW)Sep 2024Y/Y change
Revenue
1.80B65.09%
Operating expense
5.81B-30.08%
Net income
-3.79B54.16%
Net profit margin
-210.4772.24%
Earnings per share
——
EBITDA
-3.97B24.02%
Effective tax rate
——
Total assets
Total liabilities
(KRW)Sep 2024Y/Y change
Cash and short-term investments
70.45B-16.48%
Total assets
149.90B-34.10%
Total liabilities
6.08B-79.04%
Total equity
143.83B—
Shares outstanding
46.05M—
Price to book
0.91—
Return on assets
-8.32%—
Return on capital
-8.66%—
Net change in cash
(KRW)Sep 2024Y/Y change
Net income
-3.79B54.16%
Cash from operations
-4.52B7.87%
Cash from investing
32.00B121.76%
Cash from financing
-6.68M99.86%
Net change in cash
27.80B474.69%
Free cash flow
523.28M107.32%
About
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Founded
Nov 1996
Employees
72
Search
Clear search
Close search
Google apps
Main menu